[go: up one dir, main page]

WO2008034202A3 - Traitement de la sclérose latérale amyotrophique - Google Patents

Traitement de la sclérose latérale amyotrophique Download PDF

Info

Publication number
WO2008034202A3
WO2008034202A3 PCT/BE2007/000107 BE2007000107W WO2008034202A3 WO 2008034202 A3 WO2008034202 A3 WO 2008034202A3 BE 2007000107 W BE2007000107 W BE 2007000107W WO 2008034202 A3 WO2008034202 A3 WO 2008034202A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
ivermectin
derivates
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BE2007/000107
Other languages
English (en)
Other versions
WO2008034202A2 (fr
Inventor
Maria Andries
Wim Robberecht
Den Bosch Ludo Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of WO2008034202A2 publication Critical patent/WO2008034202A2/fr
Publication of WO2008034202A3 publication Critical patent/WO2008034202A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau médicament pour le traitement médical d'une maladie du neurone moteur (MND) telle que la sclérose latérale amyotrophique. Plus particulièrement, la présente invention concerne l'utilisation de l'ivermectine et d'analogues, pour prévenir, retarder et améliorer une maladie du neurone moteur (MND) telle que la sclérose latérale amyotrophique (ALS) et la dégénérescence associée des neurones moteurs.
PCT/BE2007/000107 2006-09-19 2007-09-19 Traitement de la sclérose latérale amyotrophique Ceased WO2008034202A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0618403.0 2006-09-19
GBGB0618403.0A GB0618403D0 (en) 2006-09-19 2006-09-19 Treatment of amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
WO2008034202A2 WO2008034202A2 (fr) 2008-03-27
WO2008034202A3 true WO2008034202A3 (fr) 2008-06-19

Family

ID=37421218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE2007/000107 Ceased WO2008034202A2 (fr) 2006-09-19 2007-09-19 Traitement de la sclérose latérale amyotrophique

Country Status (2)

Country Link
GB (1) GB0618403D0 (fr)
WO (1) WO2008034202A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2704709B1 (fr) 2011-05-02 2020-09-02 Altaba, Ariel Ruiz Lactones macrocycliques et leur utilisation
CN103356687B (zh) * 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
US20230028307A1 (en) * 2020-01-10 2023-01-26 Equilibre Biopharmaceuticals Bv Treatment of neurological disorders with avermectins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022302A1 (fr) * 1991-06-07 1992-12-23 Fractal Laboratories, Incorporated Traitement d'affections humaines entrainant un dereglement ou un dysfonctionnement du systeme nerveux
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
JP2002047206A (ja) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Ｇｄｎｆ産生促進剤、パーキンソン病治療剤およびａｌｓ治療剤
US20060205757A1 (en) * 2005-03-11 2006-09-14 Mingqiang Zhang 39-desmethoxyrapamycin, compositions and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022302A1 (fr) * 1991-06-07 1992-12-23 Fractal Laboratories, Incorporated Traitement d'affections humaines entrainant un dereglement ou un dysfonctionnement du systeme nerveux
FR2790670A1 (fr) * 1999-03-12 2000-09-15 Aventis Pharma Sa Association riluzole et antagoniste des recepteurs ampa
JP2002047206A (ja) * 2000-07-28 2002-02-12 Taisho Pharmaceut Co Ltd Ｇｄｎｆ産生促進剤、パーキンソン病治療剤およびａｌｓ治療剤
US20060205757A1 (en) * 2005-03-11 2006-09-14 Mingqiang Zhang 39-desmethoxyrapamycin, compositions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDRIES ET AL: "Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENCE, OXFORD, GB, vol. 25, no. 1, 21 November 2006 (2006-11-21), pages 8 - 16, XP005727015, ISSN: 0969-9961 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TAKI, SHIGEYUKI ET AL: "V-type ATPase inhibitors as GDNF formation promoters for treatment of Parkinson disease and ALS (amyotrophic lateral sclerosis )", XP002474492, retrieved from STN Database accession no. 2002:113136 *

Also Published As

Publication number Publication date
GB0618403D0 (en) 2006-11-01
WO2008034202A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2007104789A3 (fr) Dérivés d'amyline
WO2009033821A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2007109024A3 (fr) Analogues de la thiazolidinedione
WO2007128802A3 (fr) Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
WO2007127263A3 (fr) Utilisations thérapeutiques d'urolithines
WO2008043544A8 (fr) Composés de pyrazoline substitués par un groupe sulfonamide, préparation de ceux-ci et utilisation de ceux-ci en tant qu'inhibiteurs des cbl
WO2007048801A3 (fr) Medicaments augmentant le desir sexuel comprenant des derives de benzimidazolone
WO2009043518A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009002159A3 (fr) Vaccin intradermique contenant un peptide de pvh
WO2007135426A3 (fr) Traitement de maladies neurodégénératives
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2005023833A3 (fr) Traitement de maladies neurodegeneratives
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
CA2646419C (fr) Utilisation de la pentraxine longue ptx3 pour la prevention ou le traitement de maladies virales
WO2008043788A3 (fr) Nouveaux composés
WO2007147868A3 (fr) Prévention de l'atrophie musculaire
WO2008034202A3 (fr) Traitement de la sclérose latérale amyotrophique
WO2008152068A3 (fr) Dérivés de [1,10]-phénanthroline pour le traitement de maladies neurodégénératives ou hématologiques
WO2007115287A3 (fr) Combinaison de composés organiques
WO2008094054A3 (fr) Composés
WO2009074498A8 (fr) Nouvelle utilisation médicale de l'orotate de propionate de 3-(2,2,2-triméthylhydrazine)
WO2009033813A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2007009686A3 (fr) Composes de pyrazoline substituee, preparation et utilisation de ceux-ci comme medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07815686

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07815686

Country of ref document: EP

Kind code of ref document: A2